MDT
Medtronic (MDT)
NYSE
$87.23+$0.06 (+0.07%)
Price as of Aug 07, 2026 7:59 PM EDT
  • $110.0B
    Market Cap
  • -3.11%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: 53
  • Momentum Score: 67
  • True Yield: 48
  • Financial Health Score: 47
TradeSmith Loading

Latest Research & News

I'm Calling It: Medtronic (MDT) Will Soar 40% by the End of 2026

Medtronic's stock has declined over 30% in the past five years due to cost pressures and competitive challenges, but analyst Leo Sun believes it could rise 40% to $121 by end of 2026. The company's recent diabetes unit spinoff, business restructuring focused on higher-margin cardiovascular and neuroscience portfolios, and strong revenue growth (8.4% in fiscal 2026) position it for recovery. Trading at 18x forward earnings with a 3.3% dividend yield and potential Dividend King status next year, Medtronic could attract significant investor attention.

08/05/2026, 12:02 PM • The Motley Fool

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

Ceribell announced the appointment of Thomas West and Sharon O'Keefe to its Board of Directors. West, former CEO of Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B), and O'Keefe, former President of University of Chicago Medical Center, bring significant commercial and health-system leadership experience. The appointments support Ceribell's expansion as its point-of-care brain monitoring platform is now deployed in over 680 U.S. hospitals.

07/29/2026, 7:00 AM • GlobeNewswire

Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance

Implicity announced FDA 510(k) clearance for its next-generation ILR ECG Analyzer, a cloud-based AI software that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity. The manufacturer-agnostic algorithm works with devices from Abbott, Biotronik, Boston Scientific, and Medtronic, addressing a significant clinical workflow burden in remote cardiac monitoring.

07/28/2026, 7:45 AM • GlobeNewswire

Ultrasonic Aspirator Market Size Projected to Reach USD 376.32 Million by 2035 | SNS Insider

The global ultrasonic aspirator market is valued at USD 194.03 million in 2025 and is projected to reach USD 376.32 million by 2035, growing at a CAGR of 6.87%. The U.S. market is expected to grow from USD 67.49 million to USD 118.90 million by 2035, driven by increasing adoption of advanced surgical technologies, rising neurosurgery procedures, and growing demand for minimally invasive surgeries. North America leads the market with 39.80% share, while Asia-Pacific registers the fastest growth at 8.83% CAGR.

07/28/2026, 6:49 AM • GlobeNewswire

Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - Analysis by Product, Surgery, End User and Region

The global electrosurgery market is projected to grow from $8.01 billion in 2025 to $11.59 billion by 2031, with a CAGR of 6.4%. Growth is driven by increasing surgical volumes, rising chronic disease prevalence, and adoption of minimally invasive procedures. However, challenges include procedural risks, regulatory constraints, and surgeon shortages. Ambulatory surgical centers are expanding their role, while the United States leads North American growth.

07/24/2026, 10:41 AM • GlobeNewswire

[Latest] Global Implantable Cardiac Fluorine-Free Resins Market Size/Share Worth USD 4.26 Billion by 2035 at a 10.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,SWOT Analysis)

The global implantable cardiac fluorine-free resins market is valued at USD 1.52 billion in 2025 and is expected to grow to USD 4.26 billion by 2035 at a CAGR of 10.8%. Growth is driven by increasing cardiovascular disease prevalence, aging demographics, demand for biocompatible materials, and advancements in manufacturing technologies like additive manufacturing. Asia Pacific is projected to experience the fastest growth, while North America and Europe maintain steady expansion.

07/23/2026, 4:30 AM • GlobeNewswire

Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight

The global robotic endoscopy devices market is projected to grow from USD 2.8 billion in 2025 to USD 6.5 billion by 2034, driven by increasing demand for minimally invasive procedures, technological advancements in AI-enabled navigation and imaging, and rising prevalence of gastrointestinal disorders. North America leads the market with 42% share, while Asia-Pacific is expected to witness the highest growth. Key players include Intuitive Surgical, Medtronic, Johnson & Johnson MedTech, and others.

07/22/2026, 1:00 PM • GlobeNewswire

Urology Devices Market Size to Reach USD 80.0 Billion by 2035 | SNS Insider

The global urology devices market is valued at USD 39.23 billion in 2025 and is projected to reach USD 80.0 billion by 2035, growing at a CAGR of 7.35%. Growth is driven by rising demand for robotic-assisted surgery, kidney disease treatment, and minimally invasive procedures. North America leads the market while Asia Pacific records the fastest growth.

07/20/2026, 7:53 AM • GlobeNewswire

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.

07/14/2026, 12:30 AM • GlobeNewswire

Disposable Endoscopes Market Size Projected to Hit USD 10.47 Billion by 2035 | SNS Insider

The global disposable endoscopes market is expected to expand at a CAGR of 15.04% through 2035, driven by rising infection prevention initiatives, adoption of single-use endoscopes, and minimally invasive procedures. North America leads with 38.45% market share, while Asia Pacific records the fastest growth. Hospitals dominate the end-user segment with 55.36% market share, with ambulatory surgical centers showing the highest growth potential.

07/13/2026, 11:00 AM • GlobeNewswire

Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR

The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show growing segments despite tariff-related challenges.

07/10/2026, 10:56 AM • GlobeNewswire

Surgical Navigation System Report; Patent Leadership Led by the United States with 1,204 Patents In 230-Page Patent Landscape Covering Neurosurgery, Spinal, Orthopaedic, ENT, and Dental Navigation Applications

A comprehensive patent landscape analysis of surgical navigation systems reveals 2,524 patents filed globally from 2010-2025, with the United States leading at 1,204 patents. The global market was valued at USD 8.38 billion in 2024 and is projected to reach USD 18.47 billion by 2030 at a 14% CAGR. Key drivers include AI-guided support, augmented reality, and robotic integration, with North America dominating and Asia-Pacific as the fastest-growing region. Major players include Brainlab AG, Medtronic, and Stryker.

07/09/2026, 6:52 AM • GlobeNewswire

AI, Cybersecurity, and Interoperable Systems: Core Pillars Driving the Smart Hospital Evolution

The global Smart Hospitals Market is projected to grow from USD 90.82 billion in 2026 to USD 206.71 billion by 2032, with a CAGR of 14.56%. Growth is driven by AI integration, connected medical devices, and digital health initiatives across APAC, Europe, and North America. Key focus areas include precision medicine, operational efficiency, and cybersecurity implementation.

07/08/2026, 4:20 AM • GlobeNewswire

Intuitive Surgical's Moat Is Getting Stronger. Is This the Closest Thing to a 'Forever' Stock?

Intuitive Surgical maintains a dominant position in the robotic surgery market with its Da Vinci system, which benefits from strong competitive moats including surgeon training, high switching costs, and deep operating room integration. The company's recurring revenue model—driven primarily by accessories, instruments, and service contracts rather than system sales—supports steady earnings growth. Despite new competition from Medtronic's Hugo system, Intuitive Surgical's broad market presence and established leadership position its moat as increasingly stronger.

07/01/2026, 5:10 AM • The Motley Fool

Medtronic Data Breach Exposes Personal Information: Murphy Law Firm Investigates Legal Claims

Medtronic discovered a data breach in April 2026 where cybercriminals accessed its inadequately secured network, compromising sensitive personal information of hundreds of thousands of individuals including names, Social Security numbers, medical information, addresses, and dates of birth. Murphy Law Firm is investigating potential class action lawsuits to seek compensation for affected individuals.

06/30/2026, 7:26 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$84.96
$87.19
$87.16
1-Year Range
$73.75
$105.35
$87.16
Latest Close$87.16
Change
+$1.24 (+1.42%)
Volume5,056,709
Market Cap$110.0B
Shares Outstanding1.3B
P/E (TTM)23.05
Diluted EPS (TTM)$3.73
Enterprise Value$136.0B

Information as of 08/07/2026

Company Profile

$110.0B
Market Cap
$4.8B
Net Income
Sector: Healthcare
Industry: Medical Devices
Building Two, Galway, Ireland, H91 4K49
353 1 438 1700

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys

Key Executives

  • Geoffrey Straub Martha
  • Brett A. Wall
  • Michelle Quinn
  • Thierry Pieton
  • Jason Weidman

Current Ownership Distribution

  • Institutions19.6B (82.33%)
  • Mutual Funds4.2B (17.64%)
  • Insiders7.4M (0.03%)
  • Other0 (0.00%)